Cadrenal Therapeutics, Inc. Common Stock (CVKD) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Ponte Vedra, FL, アメリカ. 現CEOは Quang X. Pham.
CVKD を有する IPO日 2023-01-20, 4 名の正社員, に上場 NASDAQ Global Market, 時価総額 $12.01M.
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
